Clinical Remission of Primary Cutaneous Marginal Zone B-Cell Lymphoma in a Patient With Crohn's Disease After Helicobacter pylori Quadruple Therapy and Vedolizumab

Am J Dermatopathol. 2023 Aug 1;45(8):572-576. doi: 10.1097/DAD.0000000000002470.

Authors

Celine M Schreidah¹, Lauren M Fahmy¹, Brigit A Lapolla², Bradley D Kwinta¹, Cynthia M Magro³, Larisa J Geskin²

Affiliations

¹ Columbia University Vagelos College of Physicians and Surgeons, New York, NY.
² Department of Dermatology, Columbia University Irving Medical Center, New York, NY; and.
³ Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.

PMID: 37377200
DOI: 10.1097/DAD.0000000000002470

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Crohn Disease* / complications
Crohn Disease* / drug therapy
Helicobacter pylori*
Humans
Lymphoma, B-Cell, Marginal Zone* / drug therapy
Lymphoma, B-Cell, Marginal Zone* / pathology
Remission Induction
Stomach Neoplasms* / drug therapy

Substances

vedolizumab
Antibodies, Monoclonal, Humanized